Evotec SE

EVT

DE0005664809

Biotechnology & Medical Research

Market Closed - Xetra Other stock markets 09:05:26 17/05/2024 pm IST			After market 01:28:34 am
9.76 ^EUR	-4.97%		9.783	+0.24%

14/05	Centogene, Evotec Discover New Molecule for Potential Gaucher Disease Treatment	MT
14/05	Centogene N.V and Evotec SE Discovers Promising New Molecule to Treat Gaucher Disease	CI

EVOTEC : RBC reiterates its Buy rating

May 03, 2024 at 02:38 pm IST

Charles Weston from RBC retains his positive opinion on the stock with a Buy rating. The target price is decreased from EUR 18.60 to EUR 16.00.

Latest news about Evotec SE

Centogene, Evotec Discover New Molecule for Potential Gaucher Disease Treatment	14/05	MT
Centogene N.V and Evotec SE Discovers Promising New Molecule to Treat Gaucher Disease	14/05	CI
EVOTEC : Warburg Research reiterates its Buy rating	06/05	ZD
EVOTEC : RBC reiterates its Buy rating	03/05	ZD
Bayer: strategic collaboration with Evotec	30/04	CF
Evotec, Bayer to Collaborate on New Cardiovascular Disease Therapies	30/04	MT
Evotec, Bayer to Focus on Precision Treatments for Cardiovascular Diseases	30/04	MT
Bayer and Evotec Collaborate to Advance Precision Cardiology	30/04	CI
EVOTEC : Deutsche Bank gives a Buy rating	26/04	ZD
The specter of stagflation rears its ugly head again	25/04
EVOTEC : Buy rating from Deutsche Bank	25/04	ZD
Top Midday Decliners	25/04	MT
Dpa-AFX Overview: COMPANIES from 24.04.2024 - 15:15	24/04	DP
Sector Update: Health Care Stocks Rise Pre-Bell Wednesday	24/04	MT
Transcript : Evotec SE, 2023 Earnings Call, Apr 24, 2024	24/04
Technology Stocks Gain Amid Tesla's EV Plans as US Equity Futures Turn Mostly Higher Pre-Bell	24/04	MT
Sector Update: Health Care	24/04	MT
Top Premarket Decliners	24/04	MT
RBC upgrades Evotec to 'Outperform' after figures and outlook	24/04	DP
EVOTEC : Warburg Research reaffirms its Buy rating	24/04	ZD
Jefferies rates Evotec a 'Buy' after figures and outlook	24/04	DP
EVOTEC : Jefferies reaffirms its Buy rating	24/04	ZD
EVOTEC : RBC keeps its Buy rating	24/04	ZD
Evotec crashes - Too much uncertainty	24/04	DP
Evotec SE Reports Earnings Results for the Full Year Ended December 31, 2023	24/04	CI

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, womenâs health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.

Sector

Biotechnology & Medical Research

Calendar

22/05/2024 - Q1 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , MDAX

More about the company

Income Statement Evolution

More financial data

Ratings for Evotec SE

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

10.27 EUR

Average target price

21.99 EUR

Spread / Average Target

+114.12%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
EVOTEC SE	-54.14%	197.91Cr
MODERNA, INC.	+33.63%	5.08TCr
IQVIA HOLDINGS INC.	-0.09%	4.28TCr
LONZA GROUP AG	+49.62%	4.2TCr
CELLTRION, INC.	-4.96%	2.95TCr
ICON PUBLIC LIMITED COMPANY	+11.18%	2.61TCr
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	1.91TCr
BIO-TECHNE CORPORATION	+8.61%	1.31TCr
MEDPACE HOLDINGS, INC.	+28.31%	1.22TCr
UNITED THERAPEUTICS CORPORATION	+24.73%	1.21TCr

Other Biotechnology & Medical Research

Evotec SE

Equities

EVT

DE0005664809

Biotechnology & Medical Research

EVOTEC : RBC reiterates its Buy rating

Latest news about Evotec SE

Chart Evotec SE

Company Profile

Income Statement Evolution

Ratings for Evotec SE

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research